Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Medical Developments International Limited ( (AU:MVP) ).
Medical Developments International Limited has notified the market that 575,235 performance rights, trading under the ASX security code MVPAD, have ceased. The securities lapsed on 17 April 2026 due to the expiry of the performance rights without exercise or conversion, resulting in a reduction of potential dilution from these instruments in the company’s capital structure.
The cessation of these unexercised performance rights simplifies the company’s outstanding equity-based incentives and clarifies its issued capital profile for investors. This adjustment may have implications for the alignment of management incentives with shareholder interests, as well as for future equity-based remuneration planning by the board.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
More about Medical Developments International Limited
Medical Developments International Limited is an Australian healthcare company listed on the ASX under the code MVP. The company operates in the medical products and pharmaceuticals sector, with a focus on developing and commercialising treatments and devices for emergency medicine and related clinical applications.
Average Trading Volume: 115,041
Technical Sentiment Signal: Sell
Current Market Cap: A$43.37M
Learn more about MVP stock on TipRanks’ Stock Analysis page.